Clinical trials addressing the efficacy of indirect and direct RSPO targeting strategies through PORCNi and anti-RSPO3 antibodies respectively will hopefully provide more insight beneficial to the development of novel treatment strategies against RSPO driven cancer. Here, RSPO1 is linked to cancer.